Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada To Rethink Controversial Pricing Rules

Executive Summary

Canadian pricing body, the PMPRB, is considering relaxing screening criteria for drugs that will be subject to stricter price controls and extending grace periods for conforming with new rules.

You may also be interested in...



Pricing Reforms Prompt Canadian Business Rethink

The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.

Canada’s Drug Pricing Reform Faces Legal Challenge

Canada’s R&D drug industry says it approached the court as a “necessary step,” given the significant impact of the pricing reforms.

Canadian Drug Pricing Reforms Could Lead To Medicine Shortages

Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel